These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 3996316)
1. Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus. Campen CA; Jordan VC; Gorski J Endocrinology; 1985 Jun; 116(6):2327-36. PubMed ID: 3996316 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Jordan VC; Gosden B Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937 [TBL] [Abstract][Full Text] [Related]
3. Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor. Jordan VC; Gosden B J Steroid Biochem; 1983 Sep; 19(3):1249-58. PubMed ID: 6684713 [TBL] [Abstract][Full Text] [Related]
4. Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms. Black LJ; Goode RL Endocrinology; 1981 Sep; 109(3):987-9. PubMed ID: 7262030 [TBL] [Abstract][Full Text] [Related]
5. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Murphy CS; Parker CJ; McCague R; Jordan VC Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879 [TBL] [Abstract][Full Text] [Related]
8. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017 [TBL] [Abstract][Full Text] [Related]
9. Modulation of rat uterine progesterone receptor levels and peroxidase activity by tamoxifen citrate, LY117018, and estradiol. Keeping HS; Lyttle CR Endocrinology; 1982 Dec; 111(6):2046-54. PubMed ID: 6890442 [No Abstract] [Full Text] [Related]
10. Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Kraus WL; Katzenellenbogen BS Endocrinology; 1993 Jun; 132(6):2371-9. PubMed ID: 8504742 [TBL] [Abstract][Full Text] [Related]
11. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro. Jordan VC; Koch R; Langan S; McCague R Endocrinology; 1988 Apr; 122(4):1449-54. PubMed ID: 3345720 [TBL] [Abstract][Full Text] [Related]
12. Effects of daily anti-estrogen treatment on uterine growth and progesterone receptor concentrations in adult rat uterus. Janssens JP; Billiet G; Bonte J; De Loecker W Anticancer Res; 1984; 4(3):157-62. PubMed ID: 6465854 [TBL] [Abstract][Full Text] [Related]
13. Molecular effects of antiestrogens (tamoxifen and LY117018) on estrogen-dependent glycoprotein (USP-1) synthesized and secreted by rat uterine epithelial cells. Takeda A; Shimizu S Endocrinology; 1988 Jul; 123(1):258-63. PubMed ID: 3383775 [TBL] [Abstract][Full Text] [Related]
14. Control of progesterone receptors in fetal uterine cells in culture: effects of estradiol, progestins, antiestrogens, and growth factors. Sumida C; Lecerf F; Pasqualini JR Endocrinology; 1988 Jan; 122(1):3-11. PubMed ID: 3275538 [TBL] [Abstract][Full Text] [Related]
15. Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Jordan VC; Gosden B Mol Cell Endocrinol; 1982 Aug; 27(3):291-306. PubMed ID: 7128917 [No Abstract] [Full Text] [Related]
16. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Müller V; Jensen EV; Knabbe C Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403 [TBL] [Abstract][Full Text] [Related]
17. Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study. Shughrue PJ; Lane MV; Merchenthaler I Endocrinology; 1997 Dec; 138(12):5476-84. PubMed ID: 9389534 [TBL] [Abstract][Full Text] [Related]
18. A potent specific pure antiestrogen with clinical potential. Wakeling AE; Dukes M; Bowler J Cancer Res; 1991 Aug; 51(15):3867-73. PubMed ID: 1855205 [TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen. Löser R; Seibel K; Roos W; Eppenberger U Eur J Cancer Clin Oncol; 1985 Aug; 21(8):985-90. PubMed ID: 4043181 [TBL] [Abstract][Full Text] [Related]
20. Antiestrogen action in the uterus: biological ineffectiveness of nuclear bound estradiol after antiestrogen. Katzenellenbogen BS; Ferguson ER Endocrinology; 1975 Jul; 97(1):1-12. PubMed ID: 166821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]